Malacco E, Piazza S, Carretta R, Di Somma S, Mugellini A, Bertocchi F, Palatini P
Third Division of Internal Medicine, Ospedale L. Sacco, University of Milan, Italy.
Int J Clin Pharmacol Ther. 2002 Jun;40(6):263-9.
To compare the efficacy and tolerability of benazepril 10 mg + amlodipine 5 mg combination (BZ+AM) versus captopril 50 mg + hydrochlorothiazide 25 mg (CP+HT) combination.
405 outpatients with mild-to-moderate arterial hypertension not adequately controlled by a monotherapy with ACE inhibitors or calcium channel blockers or diuretics entered this multicenter, double-blind, randomized, parallel-group study.
After a 2-week placebo run-in, 397 patients with sitting diastolic (D) blood pressure (BP) > 95 mmHg and/or sitting systolic (S) BP > 160 mmHg were randomized to receive either BZ+AM (201 patients) or CP+HT (196 patients) once daily for 12 weeks. Main outcome measure was sitting DBP and SBP values at the end of active treatment. The response rate was defined as the proportion of patients with either a final sitting DBP < 90 mmHg or decreased by at least 10 mmHg or a sitting SBP < 150 mmHg or decreased by at least 20 mmHg from baseline.
The DBP and SBP values obtained with BZ+AM were, respectively, 2.7 and 3.7 mmHg lower than those obtained with CP+HT (both p < 0.001 vs. CP+HT). The response rate in the BZ+AM group (94.8%) was better than that observed in the CP+HT group (86.0%, p = 0.004). The incidence of adverse events was similar with the 2 treatment regimens (17.9% for both).
These data suggest a higher antihypertensive efficacy of the fixed combination BZ 10 mg+AM 5 mg as compared with CP 50 mg+HT 25 mg.
比较苯那普利10毫克+氨氯地平5毫克联合用药(BZ+AM)与卡托普利50毫克+氢氯噻嗪25毫克联合用药(CP+HT)的疗效和耐受性。
405例轻度至中度动脉高血压门诊患者,使用血管紧张素转换酶抑制剂、钙通道阻滞剂或利尿剂单药治疗未能充分控制血压,进入了这项多中心、双盲、随机、平行组研究。
经过2周的安慰剂导入期后,397例坐位舒张压(D)血压(BP)>95毫米汞柱和/或坐位收缩压(S)BP>160毫米汞柱的患者被随机分为两组,分别每日一次接受BZ+AM(201例患者)或CP+HT(196例患者)治疗,为期12周。主要观察指标为积极治疗结束时的坐位舒张压和收缩压值。缓解率定义为最终坐位舒张压<90毫米汞柱或较基线下降至少10毫米汞柱,或坐位收缩压<150毫米汞柱或较基线下降至少20毫米汞柱的患者比例。
BZ+AM组获得的舒张压和收缩压值分别比CP+HT组低2.�和3.7毫米汞柱(与CP+HT组相比,两者p<0.001)。BZ+AM组的缓解率(94.8%)优于CP+HT组(86.0%,p=0.004)。两种治疗方案的不良事件发生率相似(均为17.9%)。
这些数据表明,与CP 50毫克+HT 25毫克相比,固定复方BZ 10毫克+AM 5毫克具有更高的降压疗效。